 BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 PRNewswire Jacobio Pharma 1167.HK announced it has completed the first patient dosage of its in-house RD drug candidate Aurora A Inhibitor JAB-2485 in a Phase IIIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a highly selective small molecule Aurora A inhibitor. At ...... 